Related Experiment Video

Updated: May 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma

Eric Jourdan1, Veronique Leblond, Hervé Maisonneuve

  • 1Centre Hospitalier Regional Universitaire de Nîmes , Nîmes , France.

Leukemia & Lymphoma
|November 5, 2013
PubMed

Insights

Enzastaurin monotherapy showed minimal efficacy in heavily pretreated multiple myeloma patients. While well-tolerated, this protein kinase C inhibitor did not significantly improve response rates or time to progression.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Enzastaurin is an oral serine/threonine kinase inhibitor targeting protein kinase C (PKC) and phosphatidylinositol 3 (PI3) kinase/Akt pathways.
  • It induces apoptosis in multiple myeloma (MM) cell lines via a caspase-independent mechanism.

Purpose of the Study:

  • To evaluate the response rate, time to progression (TTP), and safety of enzastaurin monotherapy.
  • To explore biomarker associations with clinical outcomes in previously treated MM patients.

Main Methods:

  • A Phase II study enrolled 14 previously treated MM patients.
  • Patients received enzastaurin 250 mg twice daily with loading doses on day 1.

Main Results:

  • One minimal response was observed among the participants.
  • The median time to progression (TTP) was 5.11 months.
  • Grade 3 adverse events included anemia and prolonged QTc interval; no grade 4 events occurred.

Conclusions:

  • Single-agent enzastaurin was well tolerated in this heavily pretreated MM population.
  • However, it demonstrated limited effectiveness in improving response rate and TTP.
Keywords:
Multiple myelomaenzastaurinphase IIserine/threonine kinase inhibitor

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
390